SSRI Hyponatremia: A PMHNP Sodium Monitoring Protocol

Twenty-nine. That is the adjusted odds ratio for being hospitalized with low sodium during the first week on an SSRI, from a Swedish national registry study of 11,213 hyponatremia admissions and 44,801 matched controls. By week 13 it had fallen to 2.1. People who had been on an SSRI longer than three months actually had slightly lower odds than controls.

So the danger window is short, and it opens immediately. That is also the stretch of outpatient treatment where almost nobody has a lab on the calendar.

The typical miss goes like this. A 79-year-old woman on hydrochlorothiazide starts sertraline 25 mg for late-life depression, and ten days later her daughter calls to say she is foggy, nauseated, and nearly fell in the kitchen. Everyone hears a rough adjustment week or a depression that is getting worse. Her sodium is 126.

Catching it early comes down to a sodium drawn before the first dose, another on the calendar at two weeks, and a clear rule for what each result means.

The Risk Lives in the First Four Weeks

The mechanism is the syndrome of inappropriate antidiuretic hormone secretion, usually shortened to SIADH. Serotonergic antidepressants can push the body to release too much antidiuretic hormone, so the kidneys hang on to free water. The blood is diluted and the measured sodium drops, which means the patient is carrying extra water rather than running short of salt.

A 2018 case-control study in the American Journal of Medicine compared 14,359 people hospitalized for hyponatremia with 57,382 controls. For newly started antidepressants, the adjusted odds ratios were 5.50 for citalopram, 4.96 for sertraline, and 5.28 for venlafaxine. Mirtazapine came in at 2.54 and tricyclics at 1.59.

The 2021 follow-up from the same research group added the timeline. Risk spiked in week one, stayed high through the first month, and then fell away over roughly three months. The Carlat Report puts the clinical version plainly: symptoms usually show up within two to four weeks of starting a drug or raising the dose.

That last phrase changes practice more than anything else here. Going from sertraline 50 mg to 100 mg in month four reopens the same window, so the patient who tolerated the first two months without trouble is not automatically safe after an increase.

Older adults sit at the center of this, because age stacks with the other risk factors: thiazides, low body weight, and kidney disease all become more common with every decade. The broader prescribing adjustments for that group are covered in Geriatric Psychopharmacology for PMHNPs.

Who Needs a Baseline Sodium

Ordering a metabolic panel on every SSRI start would be defensible, but most clinicians target it. The Carlat Report’s 2024 review of antidepressants and hyponatremia in older adults lists the factors that should trigger a check:

• Older age, female sex, or body weight under 60 kg
• A diuretic, oxcarbazepine, carbamazepine, or a second-generation antipsychotic on the medication list
• Chronic kidney disease or hypertension
• Any prior episode of low sodium, on any drug

For a patient with one or more of those, the protocol has four parts.

• Draw a basic metabolic panel before the first dose, or before a dose increase.
• Order the repeat at the same visit, timed for day 10 to 14, which matches Carlat’s recommendation to recheck within two weeks.
• For patients stacking two or more risk factors, add a third draw around week four. The Swedish data shows risk still elevated through the first month, and this covers the rest of that window.
• Treat every dose increase exactly like a new start.

The order itself is the easy part. The recheck gets lost when nobody writes the date down, so put it in the after-visit summary and tell the family which symptoms should prompt a call before the lab is due.

Thiazide plus SSRI is one of the combinations worth recognizing on sight, alongside the other pairings in Psychiatric Medication Interactions Every PMHNP Should Have Memorized. For quick dosing reference across the common antidepressants, the free PMHNP prescribing cheat sheet keeps 42 psychiatric medications in one place.

What to Do at Each Sodium Level

The European clinical practice guideline on hyponatremia sorts results into three bands: mild at 130 to 135 mmol/L, moderate at 125 to 129, and profound below 125. Symptoms override the number in every band.

For outpatient psychiatry, that becomes a short ladder.

• At 135 or above, continue the antidepressant and keep the scheduled recheck.
• From 125 to 134 with mild or no symptoms, call the patient the same day, stop the SSRI or SNRI, and restrict fluids to 1 to 1.5 liters a day, which is the Carlat Report’s approach for mild cases. Loop in the primary care clinician and recheck until the value normalizes, usually within about two weeks.
• Below 125, or with vomiting, a seizure, drowsiness, or marked confusion at any level, send the patient to the emergency department.

Severe hyponatremia is treated in the hospital with hypertonic saline, and the correction itself is monitored closely because raising sodium too fast carries its own neurologic risk. That work belongs to the inpatient team, so the outpatient job is recognizing the problem and getting the patient there.

One practical warning when stopping a drug. Paroxetine and venlafaxine have short half-lives and can cause discontinuation symptoms within days, so tell the patient what to expect. Otherwise dizziness from discontinuation gets blamed on the sodium, or the other way around.

Switching, Restarting, and the Chart

Once the sodium has recovered, most patients still need an antidepressant. Carlat identifies bupropion and mirtazapine as the lower-risk options, and they are the usual next step.

Lower risk still needs watching. In the 2018 Swedish data, newly started mirtazapine carried an odds ratio of 2.54, about half that of the SSRIs but well above zero. A patient switched to mirtazapine after an episode deserves the same baseline and two-week recheck.

“The sodium I care most about is the one at day ten, in the eighty-year-old whose family says she’s just been more tired since the sertraline started. By the annual physical, that story is already over.”
— Lindsay Hill, DNP, PMHNP-BC

If an SSRI or SNRI is ever restarted, run it as a brand-new start with a fresh baseline and a two-week recheck, and document why the benefit justified the retry.

The chart is where most repeat episodes are prevented. After any episode, add antidepressant-associated hyponatremia to the problem list or the intolerance list, with the drug, the dose, and the lowest value. Months later a different prescriber in a different system is the one who most needs to see it.

The same habit of scheduling the lab when you write the prescription runs through QTc Monitoring for Psychotropics, and the broader approach to sorting a side effect from a symptom of the illness is laid out in Managing Psychiatric Medication Side Effects.

What Most People Get Wrong

The common mental model treats hyponatremia as a slow, cumulative problem of elderly patients who have taken antidepressants for years. Under that model, an annual metabolic panel covers it.

The registry data runs the opposite direction. Risk was highest in week one, back near baseline by three months, and below baseline for long-term users, with an odds ratio of 0.78. A routine lab drawn in month eight measures the safest stretch of the whole treatment course.

The second mistake is subtler. Early hyponatremia looks like the illness being treated: fatigue, poor concentration, low energy, and nausea that could pass for a side effect. In a depressed older adult two weeks into an SSRI, the easy reading is that the medication hasn’t kicked in yet.

So reverse the default. New confusion, unsteadiness, or a fall in the first month of an SSRI or SNRI gets a sodium drawn before anyone calls it worsening depression, and the lab takes a day.

The One Thing to Do This Week

Pick the next SSRI or SNRI start on your schedule for a patient over 65, or anyone on a thiazide. Before they leave, put two orders in: a basic metabolic panel today and another at day 10 to 14.

Then write the recheck date on the after-visit summary and tell whoever lives with the patient to call if confusion, nausea, or unsteadiness shows up before then.

That habit costs two blood draws. It catches the patient who would otherwise arrive in the emergency department with a sodium of 121 and a family convinced the depression had taken a turn. Once it is built into your order set, it stops depending on memory, and it covers every dose increase too.

This content is for educational purposes and does not replace individualized clinical judgment or supervision.